Global Rivastigmine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rivastigmine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
Rivastigmine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rivastigmine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Alzheimer's Disease and Parkinson's Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rivastigmine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Rivastigmine key manufacturers include Novartis, Sun Pharmaceutical, Alvogen, Mylan Pharmaceuticals, Teva, Dr. Reddy's Laboratories, Orchid Healthcare, APOTEX and Alembic Pharmaceuticals, etc. Novartis, Sun Pharmaceutical, Alvogen are top 3 players and held % sales share in total in 2022.
Rivastigmine can be divided into Oral and Transdermal Patch, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Rivastigmine is widely used in various fields, such as Alzheimer's Disease and Parkinson's Disease, etc. Alzheimer's Disease provides greatest supports to the Rivastigmine industry development. In 2022, global % sales of Rivastigmine went into Alzheimer's Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rivastigmine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Sun Pharmaceutical
Alvogen
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Segment by Type
Oral
Transdermal Patch
Alzheimer's Disease
Parkinson's Disease
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rivastigmine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rivastigmine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rivastigmine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rivastigmine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rivastigmine introduction, etc. Rivastigmine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Rivastigmine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Rivastigmine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rivastigmine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Alzheimer's Disease and Parkinson's Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rivastigmine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Rivastigmine key manufacturers include Novartis, Sun Pharmaceutical, Alvogen, Mylan Pharmaceuticals, Teva, Dr. Reddy's Laboratories, Orchid Healthcare, APOTEX and Alembic Pharmaceuticals, etc. Novartis, Sun Pharmaceutical, Alvogen are top 3 players and held % sales share in total in 2022.
Rivastigmine can be divided into Oral and Transdermal Patch, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Rivastigmine is widely used in various fields, such as Alzheimer's Disease and Parkinson's Disease, etc. Alzheimer's Disease provides greatest supports to the Rivastigmine industry development. In 2022, global % sales of Rivastigmine went into Alzheimer's Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rivastigmine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Sun Pharmaceutical
Alvogen
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Segment by Type
Oral
Transdermal Patch
Segment by Application
Alzheimer's Disease
Parkinson's Disease
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rivastigmine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rivastigmine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rivastigmine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rivastigmine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rivastigmine introduction, etc. Rivastigmine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Rivastigmine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices